Dorsey Wright & Associates Decreases Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dorsey Wright & Associates lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 22.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 130,887 shares of the company's stock after selling 37,975 shares during the period. Dorsey Wright & Associates' holdings in Teva Pharmaceutical Industries were worth $2,885,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of TEVA. Clal Insurance Enterprises Holdings Ltd lifted its stake in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP raised its position in shares of Teva Pharmaceutical Industries by 2.6% during the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after acquiring an additional 688,862 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after buying an additional 569,412 shares during the last quarter. State Street Corp boosted its stake in Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company's stock valued at $351,402,000 after acquiring an additional 1,778,268 shares in the last quarter. Finally, AustralianSuper Pty Ltd boosted its position in shares of Teva Pharmaceutical Industries by 16.8% in the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company's stock valued at $203,268,000 after purchasing an additional 1,329,319 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Trading Down 0.9 %

NYSE TEVA traded down $0.13 during trading hours on Thursday, hitting $15.16. 4,305,266 shares of the company's stock were exchanged, compared to its average volume of 9,683,507. The business's 50 day moving average is $16.81 and its 200-day moving average is $18.06. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The firm has a market capitalization of $17.19 billion, a P/E ratio of -10.46, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TEVA. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Bank of America decreased their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Thursday, March 27th. Finally, UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.